---
title: "Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291412026.md"
description: "Intensity Therapeutics will resume enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma trial at limited US sites, following a pause since March 2025 due to funding. Swiss regulators approved a protocol amendment for the Phase 2 INVINCIBLE-4 TNBC study, with enrollment restarting in Q3 2026. The company established a $60 million ATM facility in March 2026 and held over 20 partnership discussions at the BIO conference."
datetime: "2026-07-01T12:04:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291412026.md)
  - [en](https://longbridge.com/en/news/291412026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291412026.md)
---

# Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trial

-   Intensity Therapeutics plans to resume enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma trial at a limited number of US sites. \* Enrollment had been paused since March 2025 due to funding constraints. \* Swiss regulators cleared a protocol amendment for the Phase 2 INVINCIBLE-4 presurgical TNBC study; enrollment is slated to restart in Q3 2026. \* Set up a $60 million at-the-market facility in March 2026; cash and equivalents were $10.2 million as of March 31, 2026. \* Partnering outreach expanded, including more than 20 discussions at the 2026 BIO conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE95757) on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INTS.US](https://longbridge.com/en/quote/INTS.US.md)

## Related News & Research

- [INTS: Net loss narrowed, R&D spending fell, but continued operations depend on new funding](https://longbridge.com/en/news/295529242.md)
- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Wallix updates financial calendar, sets release of 2026 half-year results](https://longbridge.com/en/news/296258764.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)